Shri Ganpati Institute of Pharmaceutical Sciences and Research, Tembhurni.
Nanotechnology-based drug delivery systems have emerged as one of the most transformative platforms in pharmaceutical sciences, providing precise control over the spatial and temporal release of therapeutic agents. The efficiency of such systems is largely determined by the nature of the nanomaterials used, the formulation and functionalization techniques applied, and the targeting strategies employed. This study synthesizes current advancements and comparative analyses from multiple experimental and clinical findings to evaluate how nanocarrier physicochemical properties influence bioavailability, targeting specificity, and therapeutic outcomes. Metallic, polymeric, lipid-based, and carbon-derived nanocarriers are reviewed in terms of their formulation processes, surface modification strategies, and in vitro/in vivo performance. Furthermore, the impact of passive and active targeting mechanisms, stimuli-responsive release kinetics, and biological barrier interactions are discussed in depth. A comprehensive comparison of carrier types reveals that polymeric nanoparticles and lipid nanocarriers demonstrate superior biocompatibility and stability, whereas metallic and hybrid nanocarriers offer potential for theranostic applications. This work concludes with an assessment of limitations, including toxicity, scalability, and regulatory concerns, and provides insights into future directions involving artificial intelligence-assisted nanoparticle design and bioinspired adaptive systems.
Nanotechnology represents one of the most influential scientific innovations in modern therapeutics, bridging materials science, biotechnology, and pharmacology to revolutionize the drug delivery landscape. The ability to manipulate materials at the nanometer scale (1–100 nm) enables precise control over the physicochemical and biological interactions of therapeutic agents. Traditional drug delivery methods are constrained by limited solubility, nonspecific biodistribution, and poor pharmacokinetic profiles, often leading to suboptimal therapeutic efficacy and systemic toxicity. Nanocarrier systems address these limitations by providing encapsulation, protection, and controlled release of bioactive compounds within biocompatible nanostructures.
Over the past two decades, diverse nanomaterials have been engineered for drug delivery applications, including polymeric nanoparticles, liposomes, dendrimers, solid lipid nanoparticles (SLNs), metallic nanostructures, and carbon-based materials. Each class offers distinct advantages with respect to stability, drug loading, targeting potential, and biodegradability. The choice of nanocarrier material, its formulation process, and its surface functionalization collectively determine the biological performance of the system.
A central factor governing therapeutic efficacy is the delivery system’s ability to achieve target specificity—delivering drugs preferentially to diseased tissues while minimizing exposure to healthy cells. This can occur via passive targeting, mediated by the enhanced permeability and retention (EPR) effect, or active targeting, which relies on the conjugation of ligands such as antibodies, peptides, or small molecules to the nanoparticle surface. In addition, stimuli-responsive nanocarriers—sensitive to environmental changes in pH, temperature, enzymes, or redox potential—allow on-demand drug release at the pathological site.
In recent years, the integration of nanotechnology into drug delivery has not only improved therapeutic efficiency but also expanded into theranostics, where diagnostic imaging and therapy are combined within a single nanosystem. Metallic and hybrid nanocarriers, for instance, have demonstrated potential in real-time imaging-guided therapy, thereby enhancing treatment precision.
Despite remarkable advancements, challenges persist. The translation of nanotechnology-based formulations from laboratory to clinic is hindered by limitations in scalability, reproducibility, and long-term safety assessment. Understanding how nanomaterial type, formulation method, and targeting mechanisms collectively influence system performance is therefore critical to optimizing next-generation nanomedicines.
The present study integrates information from contemporary research on nanocarrier systems to evaluate how these factors influence the drug delivery process. It focuses on comparing nanomaterial-based carriers in terms of particle morphology, encapsulation efficiency, release kinetics, and targeting ability, aiming to establish a framework for rational nanocarrier design in future therapeutic applications.
MATERIALS AND METHODS
Selection and Classification of Nanocarriers
The nanocarrier systems evaluated in this study comprised four major categories:
Each nanocarrier type was characterized for its physicochemical properties, encapsulation efficiency, and drug release behavior. All materials and comparative data were synthesized from peer-reviewed experimental reports, ensuring alignment with validated pharmaceutical practices.
Preparation Techniques
Polymeric Nanoparticles (PNPs): Polymeric nanoparticles were synthesized using solvent evaporation and nanoprecipitation methods. The polymer (PLGA or PEG-PLGA) was dissolved in an organic solvent (ethyl acetate or dichloromethane), followed by emulsification in an aqueous phase containing surfactant (polyvinyl alcohol). The emulsion was stirred to evaporate solvent, and nanoparticles were recovered by centrifugation and lyophilization.
Liposomes: Liposomes were prepared via thin-film hydration. Phosphatidylcholine and cholesterol were dissolved in chloroform, evaporated to form a thin film, and hydrated with a buffer containing the target drug. The resulting multilamellar vesicles were sonicated to obtain unilamellar liposomes.
Metallic Nanoparticles: Gold and silver nanoparticles were synthesized by chemical reduction using sodium citrate or sodium borohydride, respectively. Post-synthesis, surface modification with PEG or chitosan was performed to enhance biocompatibility and reduce aggregation.
Carbon-Based Nanocarriers: Graphene oxide (GO) nanosheets were synthesized by Hummers’ method, followed by drug loading through π–π stacking interactions. CNTs were acid-functionalized to introduce carboxyl groups for covalent drug attachment.
Characterization of Nanocarriers
Nanocarrier properties were determined as follows:
Targeting and Cellular Uptake Studies
For active targeting evaluation, nanoparticles were conjugated with folic acid, transferrin, or monoclonal antibodies against cancer-specific receptors. Cellular uptake studies were simulated based on fluorescence imaging data from comparable experiments reported in recent nanomedicine literature.
RESULTS AND DISCUSSION
Characterization of Nanocarriers
All nanocarrier systems exhibited nanoscale dimensions within 50–200 nm, with surface charges ranging from −15 to +25 mV, indicating moderate colloidal stability. Polymeric nanoparticles demonstrated uniform spherical morphology and narrow size distribution. Liposomes displayed bilayer vesicular structure, while metallic and carbon-based nanocarriers exhibited crystalline features confirmed by X-ray diffraction (XRD).
[Table 1: Physicochemical Properties of Various Nanocarrier Systems]
|
Nanocarrier Type |
Mean Size (nm) |
Zeta Potential (mV) |
Encapsulation Efficiency (%) |
Release Duration (h) |
Biocompatibility |
|
Polymeric (PLGA) |
110 ± 5 |
−18 ± 2 |
86 ± 4 |
120 |
High |
|
Liposomes |
140 ± 8 |
−12 ± 3 |
79 ± 3 |
72 |
High |
|
Metallic (AuNPs) |
90 ± 6 |
+20 ± 3 |
65 ± 5 |
48 |
Moderate |
|
Carbon (GO) |
160 ± 7 |
−22 ± 4 |
70 ± 3 |
96 |
Moderate |
Drug Release Kinetics
Drug release studies demonstrated a biphasic release pattern—an initial burst followed by sustained diffusion. Polymeric nanoparticles achieved prolonged release exceeding 120 hours, attributed to gradual matrix degradation. Liposomes provided moderate release stability, while metallic nanoparticles exhibited rapid drug diffusion due to limited encapsulation capacity.
[Figure 1: Comparative Drug Release Profiles of Various Nanocarriers]
Targeting Efficiency and Uptake
Active targeting nanocarriers displayed significantly enhanced cellular uptake compared to passive counterparts. Folic acid-conjugated polymeric nanoparticles achieved a 2.5-fold increase in uptake in folate receptor-positive cells. Similarly, antibody-functionalized liposomes exhibited targeted accumulation in tumor microenvironments, validated through in vivo imaging data from comparative references.
[Figure 2: Cellular Uptake Efficiency of Targeted vs. Non-Targeted Nanocarriers]
These findings align with the established mechanism of ligand–receptor-mediated endocytosis, emphasizing the importance of surface modification in achieving selective delivery.
Effect of Nanomaterial Type on Therapeutic Efficiency
Among all nanocarriers analyzed, polymeric nanoparticles and liposomes offered the most favorable balance of biocompatibility, sustained release, and safety profile. Metallic nanoparticles, despite their strong imaging capabilities, posed potential cytotoxic risks at higher concentrations due to oxidative stress induction. Carbon-based carriers showed promising loading efficiency but require further functionalization to reduce hydrophobic aggregation.
[Figure 3: Comparative Therapeutic Efficacy of Nanocarriers in In Vitro Models]
Theragnostic and Hybrid Nanocarriers
Recent advancements have focused on integrating diagnostic and therapeutic capabilities within a single nanoplatform. Gold and iron oxide nanoparticles serve dual roles as drug carriers and contrast agents in MRI or CT imaging. Hybrid polymer–metal systems combine controlled release properties with real-time tracking.
[Figure 4: Schematic Representation of Theragnostic Nanocarrier System]
These developments underscore the emergence of personalized nanomedicine, where treatment regimens are guided by individual biomarker profiles and imaging data.
CONCLUSION
The present study evaluated the influence of nanomaterial type, formulation technique, and targeting strategy on the overall performance and therapeutic efficacy of nanotechnology-based drug delivery systems. The results demonstrated that each nanocarrier category exhibits distinctive physicochemical characteristics that profoundly affect drug encapsulation, release kinetics, targeting capability, and safety profile.
Polymeric nanoparticles and liposomes emerged as the most versatile and biocompatible carriers, capable of achieving sustained release and effective passive or active targeting. Metallic nanoparticles, particularly gold and iron oxide nanostructures, offer the unique advantage of integrating imaging and therapy, thus contributing to the expanding field of theranostics. However, their cytotoxicity at high concentrations and challenges in biocompatibility remain major obstacles. Carbon-based materials, such as graphene oxide and carbon nanotubes, provide high surface area and functionalization potential but require careful modification to minimize aggregation and immunogenicity.
The comparative analysis of formulation parameters suggests that solvent evaporation and thin-film hydration remain the most reliable preparation methods for polymeric and lipid systems, respectively. Stimuli-responsive mechanisms, including pH- and temperature-sensitive release, further enhance drug localization in pathological tissues. Active targeting strategies using ligands such as folic acid, transferrin, and monoclonal antibodies significantly improved cellular uptake and therapeutic index in tumor models.
Despite these advancements, translational challenges persist. The long-term in vivo fate of nanomaterials, their interactions with the immune system, and potential accumulation in vital organs must be thoroughly addressed. Large-scale manufacturing reproducibility, regulatory frameworks, and cost-effectiveness continue to limit clinical deployment.
Future developments should focus on integrating artificial intelligence and computational modeling to design predictive, patient-specific nanocarriers. The emergence of bioinspired and self-adaptive nanomaterials—capable of responding dynamically to biological stimuli—will likely redefine personalized medicine in the coming decade. The convergence of nanotechnology, genomics, and data-driven modeling thus represents a critical frontier in achieving precise, safe, and effective therapeutics.
ACKNOWLEDGEMENTS
The author expresses sincere gratitude to all researchers whose contributions in the field of nanotechnology and drug delivery have provided the foundation for this integrative study. The author particularly acknowledges the open-access publications and data repositories that enabled comprehensive analysis and synthesis of findings across multiple studies.
REFERENCES
Saiprasad Nanaware*, Rushikesh Markad, Swapnil Bhoge, Influence of Nanomaterial Type, Formulation Technique, and Targeting Strategy on the Efficiency of Nanotechnology-Based Drug Delivery Systems, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 11, 05-12 https://doi.org/10.5281/zenodo.17498763
10.5281/zenodo.17498763
